Abstract
Major progress in the treatment of multiple myeloma has been made in the last several years. However, myeloma remains incurable and patients with high-risk cytogenetics or advanced stage disease have an even worsen survival. Only allogeneic transplantation may have curative potential in some patients. However, the high non-relapse mortality and incidence of chronic graft-versus-host disease have raised controversy regarding this procedure. In this review, we will address the role of upfront and delayed allogeneic transplant.
Original language | English (US) |
---|---|
Pages (from-to) | 105-122 |
Number of pages | 18 |
Journal | Oncology and Therapy |
Volume | 10 |
Issue number | 1 |
DOIs | |
State | Published - Jun 2022 |
Keywords
- Allogeneic transplantation
- CAR-T cell therapy
- Chronic graft-versus-host disease
- Multiple myeloma
ASJC Scopus subject areas
- Oncology